Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires AB Sanitas

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m.

AB Sanitas sells about 390 generic products in nine Central and Eastern European countries. Its largest markets are Poland, Russia and Lithuania.

Valeant said the major shareholders of AB Sanitas have agreed to sell an 87 per cent stake in the company. That portion of the deal is expected to close during the third quarter, and Valeant said it will then start an offer for the remaining shares.

The Ontario-based company expects to assume €50m ($70.3m) in debt as part of the deal. The acquisition is expected to close during the fourth quarter of 2011.

AB Sanitas is based in Kaunas and develops its own dermatology, ophthalmology and hospital injectable drugs.

26th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics